Literature DB >> 1418863

The effects of deprenyl on methamphetamine-induced dopamine depletions.

S K Johnson1, D Medina, G C Wagner.   

Abstract

The effects of deprenyl on methamphetamine-induced dopamine depletions were studied in mice. Four SC injections of 12.5 mg/kg of methamphetamine at two-hour intervals caused substantial (72-82%) and long-lasting depletions of striatal dopamine. Pretreatment with either 25 or 40 mg/kg of deprenyl did not significantly alter the magnitude of this depletion. These results indicate that, unlike what is observed following MPTP, there is no protection afforded dopaminergic cells by deprenyl pretreatment in the methamphetamine model of parkinsonism.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1418863     DOI： 10.1007/bf01245358

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  12 in total

1.  The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors:  W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

2.  The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

Authors:  J W Tetrud; J W Langston
Journal:  Science       Date:  1989-08-04       Impact factor: 47.728

3.  Methamphetamine-induced neuronal damage: a possible role for free radicals.

Authors:  M J De Vito; G C Wagner
Journal:  Neuropharmacology       Date:  1989-10       Impact factor: 5.250

4.  Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.

Authors:  E Csanda; M Tárczy
Journal:  Acta Neurol Scand Suppl       Date:  1983

5.  Deprenyl (selegiline) in the treatment of Parkinson's disease.

Authors:  W Birkmayer
Journal:  Acta Neurol Scand Suppl       Date:  1983

6.  Deprenyl (selegiline) in combination treatment of Parkinson's disease.

Authors:  F Gerstenbrand; G Ransmayr; W Poewe
Journal:  Acta Neurol Scand Suppl       Date:  1983

7.  Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

Authors:  G Cohen; P Pasik; B Cohen; A Leist; C Mytilineou; M D Yahr
Journal:  Eur J Pharmacol       Date:  1984-10-30       Impact factor: 4.432

8.  Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.

Authors:  T S Elizan; D A Moros; M D Yahr
Journal:  Arch Neurol       Date:  1991-01

9.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.

Authors:  R E Heikkila; L Manzino; F S Cabbat; R C Duvoisin
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

10.  Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.

Authors:  L I Golbe; A N Lieberman; M D Muenter; J E Ahlskog; G Gopinathan; A N Neophytides; S H Foo; R C Duvoisin
Journal:  Clin Neuropharmacol       Date:  1988-02       Impact factor: 1.592
View more
  2 in total

1.  Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion.

Authors:  K Grasing; R Azevedo; S Karuppan; S Ghosh
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

2.  Sexual differences in sensitivity to methamphetamine toxicity.

Authors:  G C Wagner; T L Tekirian; C T Cheo
Journal:  J Neural Transm Gen Sect       Date:  1993
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.